Advanced/Metastatic Solid Tumors

SOTIO is conducting a multicenter open-label Phase 1/1b study (NCT04234113) to evaluate the safety and preliminary efficacy of SOT101 (formerly SO-C101) as monotherapy and in combination with pembrolizumab in patients with selected relapsed/refractory advanced/metastatic solid tumors. The trial will enroll up to 136 subjects at leading global institutions in the U.S. and EU, including Institut Gustave Roussy (France), Centre Léon Bérard (France), Institut Claudius Regaud (France), Vall d’Hebron Institute of Oncology (Spain) Yale Cancer Center (U.S.), MD Anderson Cancer Center (U.S.) and Masaryk Memorial Cancer Institute (Czech Republic).